CU20200075A7 - Antígeno quimérico que comprende el dominio extracelular de pd-l1 - Google Patents

Antígeno quimérico que comprende el dominio extracelular de pd-l1

Info

Publication number
CU20200075A7
CU20200075A7 CU2020000075A CU20200075A CU20200075A7 CU 20200075 A7 CU20200075 A7 CU 20200075A7 CU 2020000075 A CU2020000075 A CU 2020000075A CU 20200075 A CU20200075 A CU 20200075A CU 20200075 A7 CU20200075 A7 CU 20200075A7
Authority
CU
Cuba
Prior art keywords
chimeric antigen
extracellular domain
multimer
receptors
ligand
Prior art date
Application number
CU2020000075A
Other languages
English (en)
Other versions
CU24705B1 (es
Inventor
Ávila Marta Ayala
Romero Mónica Bequet
Pérez Vladimir Armando Besada
Ayala Camila Canaán-Haden
Rodríguez Luis Ariel Espinosa
COWLEY Jorge Víctor GAVILONDO
Blanco Sonia González
Moya Isabel González
Fernández Miladys Limonta
DÍAZ Yanelys MORERA
Ramírez Javier Sánchez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000075A priority Critical patent/CU24705B1/es
Priority to CN202180072039.2A priority patent/CN116783221A/zh
Priority to EP21806135.6A priority patent/EP4234029A1/en
Priority to JP2023524660A priority patent/JP7585480B2/ja
Priority to AU2021363436A priority patent/AU2021363436A1/en
Priority to KR1020237015994A priority patent/KR20230107810A/ko
Priority to CA3196460A priority patent/CA3196460A1/en
Priority to PCT/CU2021/050008 priority patent/WO2022083805A1/es
Priority to US18/033,035 priority patent/US20230390369A1/en
Priority to MX2023004718A priority patent/MX2023004718A/es
Publication of CU20200075A7 publication Critical patent/CU20200075A7/es
Publication of CU24705B1 publication Critical patent/CU24705B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Antígeno quimérico que comprende el dominio extracelular del ligando 1 del receptor proteico de muerte celular programada 1 (PD-L1) humano y que forma un multímero que tiene reducida la capacidad de unión a los receptores PD-1 y CD80 respecto a la forma nativa de PD-L1. La composición farmacéutica que comprende dicho antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable.</p>
CU2020000075A 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1 CU24705B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1
CN202180072039.2A CN116783221A (zh) 2020-10-22 2021-09-28 包含pd-l1的胞外结构域的嵌合抗原
EP21806135.6A EP4234029A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
JP2023524660A JP7585480B2 (ja) 2020-10-22 2021-09-28 Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
AU2021363436A AU2021363436A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
KR1020237015994A KR20230107810A (ko) 2020-10-22 2021-09-28 Pd-l1의 세포 외 도메인을 포함하는 키메라 항원
CA3196460A CA3196460A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
PCT/CU2021/050008 WO2022083805A1 (es) 2020-10-22 2021-09-28 Antígeno quimérico que comprende el dominio extracelular de pd-l1
US18/033,035 US20230390369A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
MX2023004718A MX2023004718A (es) 2020-10-22 2021-09-28 Antigeno quimerico que comprende el dominio extracelular de pd-l1.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Publications (2)

Publication Number Publication Date
CU20200075A7 true CU20200075A7 (es) 2022-05-11
CU24705B1 CU24705B1 (es) 2024-06-11

Family

ID=78598633

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Country Status (10)

Country Link
US (1) US20230390369A1 (es)
EP (1) EP4234029A1 (es)
JP (1) JP7585480B2 (es)
KR (1) KR20230107810A (es)
CN (1) CN116783221A (es)
AU (1) AU2021363436A1 (es)
CA (1) CA3196460A1 (es)
CU (1) CU24705B1 (es)
MX (1) MX2023004718A (es)
WO (1) WO2022083805A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189420A1 (en) * 2024-03-14 2025-09-18 Topmunnity Therapeutics Taiwan Limited Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof
WO2026008026A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Pd-l1 cancer vaccines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
EP2468765B1 (en) * 2006-03-03 2015-04-22 ONO Pharmaceutical Co., Ltd. Tetramer of extracellular domain of PD-L1
CA2850245C (en) * 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
US20160206732A1 (en) 2013-05-14 2016-07-21 Shanghai Hycharm Inc. Epitope vaccine for low immunogenic protein and preparing method and usage thereof
WO2015178746A1 (ko) * 2014-05-23 2015-11-26 주식회사 제넥신 Pd-l1 융합 단백질 및 이의 용도
AU2017266905B2 (en) * 2016-05-18 2022-12-15 Albert Einstein College Of Medicine, Inc. Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
CA3056807A1 (en) 2017-03-17 2018-09-20 Vaximm Ag Novel pd-l1 targeting dna vaccine for cancer immunotherapy
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
AU2021363436A9 (en) 2024-10-10
KR20230107810A (ko) 2023-07-18
WO2022083805A1 (es) 2022-04-28
US20230390369A1 (en) 2023-12-07
CN116783221A (zh) 2023-09-19
AU2021363436A1 (en) 2023-06-01
JP7585480B2 (ja) 2024-11-18
JP2023546485A (ja) 2023-11-02
EP4234029A1 (en) 2023-08-30
CA3196460A1 (en) 2022-04-28
CU24705B1 (es) 2024-06-11
MX2023004718A (es) 2023-05-10

Similar Documents

Publication Publication Date Title
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
CR20210042A (es) RECEPTORES DE ANTÍGENOS QUIMÉRICOS DIRIGIDOS A BCMA Y MÉTODOS DE USO DE ESTOS (Divisional 2019-0050)
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
PE20190115A1 (es) Anticuerpos vista antihumanos y su uso
MX2020010035A (es) Receptores de celulas t anti-papilomavirus 16 e7 humano.
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
MX2022015399A (es) Conjugados de superficie celular y composiciones y metodos celulares relacionados.
CL2018003520A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco.
MX2017006865A (es) Receptores de células t de kras anti-mutado.
MX2017007136A (es) Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
GEP20227453B (en) Glp-1 receptor agonists and uses thereof
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
MX2021013774A (es) Compuestos anticancerigenos dirigidos a los receptores hormonales nucleares.
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
MX2020004094A (es) Metodos para administrar inmunoterapia con receptores de antigeno quimerico.
CL2018000983A1 (es) Composiciones y métodos para producir cetosis elevada y sostenida (divisional de solicitud n°02802-2015).
MX2020003117A (es) Receptores de celulas t restringidas a hla de clase ii contra ras mutado.
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
PE20241349A1 (es) Anticuerpos de union a cd3
MX2020001358A (es) Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso.
BR112019014986A2 (pt) anticorpo que alveja bcma e uso do mesmo
CO2017000507A2 (es) Receptor quimérico de antígeno bcma
CU24705B1 (es) Antígeno quimérico que comprende el dominio extracelular de pd-l1
MX2017016851A (es) Anticuerpo para el ligando del factor 1 de muerte celular programada (pdl-1), composicion farmaceutica del mismo y uso de los mismos.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.